Search results for "R2"

A randomized, open-label, multicentre, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy based treatment strategy …

2017

TPS1115 Background: Although endocrine based therapy is recommended as first-line treatment in metastatic breast cancer (MBC) in patients with an HER2-/HR+ tumour up to 50% of the patients receive chemotherapy. Palbociclib (P) a CDK4/6 inhibitor improves PFS by 42% in endocrine sensitive and resistant HER2-/HR+ MBC when added to an endocrine therapy (ET). Patients included in clinical trials are often criticised not to be representative for real world breast cancer patients. Methods: Patients with first-line HER2-/HR+ MBC who are candidate for mono-chemotherapy will be eligible to be randomised 1:1 to receive either P plus ET per label or mono-chemotherapy per investigator´s choice with or…

The HERBA trial: a retrospective study on patients (pts) with HER2-positive (HER2+ve) breast cancer (BC) and brain metastases (BMs)

2017

Therapie des fortgeschrittenen hormonrezeptor(HR)-positiven HER2-negativen Mammakarzinoms

2020

ZusammenfassungDer Artikel gibt einen Überblick über die aktuellen Therapieoptionen des metastasierten hormonrezeptorpositiven und HER2-negativen Mammakarzinoms. Im Fokus stehen Kombinationstherapien z. B. mit CDK4/6-Inhibition im Vergleich zu rein endokrin basierten Therapien in Prä- und Postmenopause mit Darlegung der neuesten Studienergebnisse. Die Hinzunahme eines CDK4/6-Inhibitors zu einer endokrin basierten Therapie mit Aromataseinhibitor oder Fulvestrant führt zu einer deutlichen Verbesserung des progressionsfreien Überlebens und ist vorteilhaft unabhängig davon, ob es sich um Palbociclib, Ribociclib oder Abemaciclib handelt. Der daher besondere klinische Stellenwert der Inhibition c…

Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)

2021

Purpose: The most appropriate therapy for HR + /HER2-positive (HER2 +) advanced breast cancer (ABC) is a matter of debate. Co-targeting of both receptors represents an attractive strategy to overcome the cross-talk between them. Methods: The HERMIONE 9 is an observational retrospective multicentric study which aimed to describe the clinical outcome of patients with HR + /HER2 + ABC who received the combination of Fulvestrant (F) and Trastuzumab (T) as part of their routine treatment at 10 Italian Institutions. Results: Eighty-seven patients were included. Median age was 63 (range, 35–87) years. The median number of previous treatments was 3 (range, 0–10) and F and T were administered as ≥ 3…

Precision medicine in breast cancer: reality or utopia?

2017

International audience; Many cancers, including breast cancer, have demonstrated prognosis and support advantages thanks to the discovery of targeted therapies. The advent of these new approaches marked the rise of precision medicine, which leads to improve the diagnosis, prognosis and treatment of cancer. Precision medicine takes into account the molecular and biological specificities of the patient and their tumors that will influence the treatment determined by physicians. This new era of medicine is accessible through molecular genetics platforms, the development of high-speed sequencers and means of analysis of these data. Despite the spectacular results in the treatment of cancers inc…

ECR2:n suihkulinjan ja HIISIn tyhjiöpumppujen suojaus HIISIn hajamagneettikentältä

2017

Tässä työssä suunniteltiin HIISIn tyhjiöpumpuille ja ECR2:n injektiolinjalle magneettiset suojaukset HIISIn kelojen synnyttämältä magneettikentältä. HIISIn aiheuttaman magneettikentän suuruutta ja suuntaa tutkittiin simulaatioiden ja mittausten avulla suojattavissa paikoissa. Tyhjiöpumppujen valmistajat ovat ilmoittaneet kunkin pumpun kestämät maksimimagneettivuot radiaalisesti sekä aksiaalisesti. Tyhjiöpumpuille suunniteltiin ferromagneettiset suojat, jotka pienentävät HIISIn hajakenttää tyhjiöpumppujen kohdalla riittävästi, jotta pumput eivät ole vaarassa vaurioitua HIISIä käytettäessä. Suojiksi valittiin toisesta päästä suljetut putket, jotka koostuvat matalahiilipitoisesta rakenneteräsl…

Direct Toll-Like Receptor-Mediated Stimulation of Hematopoietic Stem and Progenitor Cells Occurs In Vivo and Promotes Differentiation Toward Macropha…

2012

Abstract As Toll-like receptors (TLRs) are expressed by hematopoietic stem and progenitor cells (HSPCs), they may play a role in hematopoiesis in response to pathogens during infection. We show here that TLR2, TLR4, and TLR9 agonists (tripalmitoyl-S-glyceryl-L-Cys-Ser-(Lys)4 [Pam3CSK4], lipopolysaccharide [LPS], and CpG oligodeoxynucleotide [ODN]) induce the in vitro differentiation of purified murine lineage negative cells (Lin−) as well as HSPCs (identified as Lin− c-Kit+ Sca-1+ IL-7Rα− [LKS] cells) toward macrophages (Mph), through a myeloid differentiation factor 88 (MyD88)-dependent pathway. In order to investigate the possible direct interaction of soluble microorganism-associated mol…

N=2 topological gauge theory, the Euler characteristic of moduli spaces, and the Casson invariant

1991

We discuss gauge theory with a topological N=2 symmetry. This theory captures the de Rham complex and Riemannian geometry of some underlying moduli space $\cal M$ and the partition function equals the Euler number of $\cal M$. We explicitly deal with moduli spaces of instantons and of flat connections in two and three dimensions. To motivate our constructions we explain the relation between the Mathai-Quillen formalism and supersymmetric quantum mechanics and introduce a new kind of supersymmetric quantum mechanics based on the Gauss-Codazzi equations. We interpret the gauge theory actions from the Atiyah-Jeffrey point of view and relate them to supersymmetric quantum mechanics on spaces of…

Deformation quantization of covariant fields

2002

After sketching recent advances and subtleties in classical relativistically covariant field theories, we give in this short Note some indications as to how the deformation quantization approach can be used to solve or at least give a better understanding of their quantization.

Hypoallergenic fragment of Par j 2 increases functional expression of Toll-like receptors in atopic children.

2006

Background: Parietaria judaica (Par j) is one of the main causes of allergy in the Mediterranean countries. The activation of Toll-like receptor 4 (TLR4) by lipopolysaccharide (LPS) inhibits nasal inflammation of atopic children. Objective:  To examine, in vivo and in vitro, the effect of recombinant Par j 2 (rPar j 2) and of its fragments (1–55 and 52–102) on atopic children. Methods:  We used skin prick test for in vivo evaluations. We assessed, in vitro, in peripheral blood mononuclear cells (PBMC), the effect of rPar j 2 and of the two fragments on neutrophil chemotaxis, on CD45RO, on TLR2 and TLR4 expression, on LPS binding and on interferon (IFN)-γ release, by a microchemotaxis chambe…